'This is our Black Friday' Garden centers prepare for Mother's Day rush
DES MOINES, Iowa – Garden Centers across the metro are seeing a large volume of customers over Mother's Day weekend.
Stephanie Canoyer, the Co-Owner of Canoyer Garden Center, said that Mother's Day weekend is one of the garden center's busiest.
Walk in Ankeny supports efforts for type 1 diabetes cure
'It's been a lot of prep work, but it has been crazy. This is, this is our Black Frida,y for the next probably three weeks. So, you can imagine that it's just kind of going, going, going all day long. Restocking, restocking, restocking and helping customers,' Canoyer said.
Canoyer said that this Mother's Day is the perfect time to get plants in the ground.
'The next ten days are perfect for Iowa, so we're really excited. We're ready to have a true spring and have lovely weather for all of this. So, we should be good to go. Ready to plant,' Canoyer said,
To learn more about Canoyer Garden Center visit its website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
6 hours ago
- USA Today
New report finds Disneyland, Disney World contribute $67B to US economy
New report finds Disneyland, Disney World contribute $67B to US economy Show Caption Hide Caption Disneyland celebrates 70th anniversary with deals, new attractions Customers can access discounted ticket prices and see new shows over the summer at Disneyland. Scripps News Disneyland and Walt Disney World generate nearly $67 billion in annual economic impact and support more than 403,000 U.S. jobs, according to new report commissioned by Disneyland. Disney's domestic parks contribute almost as much to the U.S. economy as consumers spend on Valentine's Day, Mother's Day, and Halloween combined. You don't need to be an economist to know that Disneyland and Walt Disney World bring in a lot of money, but for the first time, Disney is sharing just how much its domestic theme park resorts contribute to the overall U.S. economy. A new report commissioned by Disneyland and prepared by economists at Tourism Economics found that California and Florida resorts generated nearly $67 billion in annual economic impact and supported more than 403,000 direct and indirect jobs across the U.S. Prior to this report, Disney hadn't measured its impacts beyond the parks' local economies. 'To add some color to this number, consider that the two resorts' total combined impact of nearly $67 billion was nearly as much as U.S. consumers spent on Valentine's Day, Mother's Day, and Halloween combined in 2024,' said Michael Marianna, head economist for Tourism Economics, which is a subsidiary of Oxford Economics, the largest group of private economists worldwide. Disney again? Why fans keep going back to Disney parks The report attributes one in eight Central Florida jobs to Disney and nearly one in 20 jobs in Orange County, California, where Disneyland is celebrating its 70th anniversary. Disney notes it also fuels thousands of small businesses, which provide everything 'from the paint used on Sleeping Beauty Castle to specialty popcorn served in the theme parks.' 'Our destinations create economies far beyond the gates of our parks, and when we invest in the groundbreaking experiences that only Disney can deliver, growth follows,' Disney Experiences Chairman Josh D'Amaro said in a press release. In 2023, Disney pledged to invest $60 billion over the next decade to 'turbocharge' growth across its Experiences segment, which includes domestic and international parks as well as Disney Cruise Line. Half of that money is earmarked for U.S. parks, including Magic Kingdom's largest expansion to date, doubling the size of Avengers Campus at Disney California Adventure, and building new lands and attractions like Disney's first Monster's Inc. land at Disney's Hollywood Studios and new 'Coco' and 'Avatar'-inspired attractions at Disneyland Resort.
Business Upturn
a day ago
- Business Upturn
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
By GlobeNewswire Published on June 4, 2025, 17:30 IST June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ('Biodexa' or the 'Company') (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ('T1D'). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course. Tolimidone in T1D Tolimidone's potential utility in T1D has been demonstrated by a number of preclinical studies conducted at the University of Alberta, where Lyn kinase was identified as a key factor for beta cell survival and proliferation in in vitro and in vivo models. Most importantly, tolimidone was able to induce proliferation in beta cells isolated from human cadavers. About Tolimidone Tolimidone was originally discovered by Pfizer Inc. ('Pfizer') and was developed through Phase II for the treatment of gastric ulcers. Pfizer undertook a broad pre-clinical program to characterize the pharmacology, pharmacokinetics, metabolism and toxicology of tolimidone. Pfizer discontinued development of the drug due to lack of efficacy for that indication in a Phase 2 clinical trial. Tolimidone is a selective activator of the enzyme Lyn kinase which increases phosphorylation of insulin substrate -1, thereby amplifying the signalling cascade initiated by the binding of insulin to its receptor. About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR ( m ammalian T arget O f R apamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit Forward-Looking Statements Certain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 days ago
- Yahoo
Reclusive Country Star, 54, Gushes About Faith Hill: 'Most Kind and Most Generous'
has been a darling of country music since the early 1990s. She appears to have a picture-perfect life with husband and fellow major country star Tim McGraw and their three daughters, Gracie, 28, Maggie, 26, and Audrey, 23. But what might be nice for fans to know is that Hill is just as kind as she appears. On a Mother's Day post about Hill from youngest daughter Audrey, fellow country star Chely Wright, 54, made her true feelings known about Hill — and had nothing but wonderful things to say. "@audreymcgraw, your mom has always been the nicest, sweetest, most kind and most generous person around. This video took me way back in time.❤️," wrote Wright on the undated video of Hill from approximately 1994. Wright was a contemporary of Hill's in the 1990s, charting the hits "Shut Up and Drive," "Just Another Heartache," "It Was," "Single White Female" and "Jezebel," among others. But she was a closeted lesbian and was terrified that if she came out, she would be ostracized in country music. So she had romantic relationships with such country stars as Vince Gill and Brad Paisley, both prior to their current marriages to Amy Grant and Kimberly Williams, respectively. In Wright's memoir, she writes about how in 2005, her friend and fellow country artist John Rich, told her that it wouldn't be OK to come out of the closet because "people don't approve of that deviant behavior" because "it's a sin." Wright eventually came out of the closet publicly in 2010 after she left Nashville for New York City. After she came out, she received a plethora of support from female country stars, including Hill, Mary Chapin Carpenter, LeAnn Rimes, , the band SheDaisy and the late Naomi Judd. Carpenter, Rimes and the sisters of SheDaisy supported her publicly; she told the Huffington Post that Hill, Yearwood and Judd all reached out privately after she came out. She said no male country stars made any moves of support. Either way, Wright left music altogether during the pandemic and is now happily working as the senior vice president of corporate social responsibility and new market growth at the global workplace experience and facilities management company ISS. 'I know firsthand what it feels like to be afraid that you don't fit in at work,' Wright told Us Weekly in a 2025 interview, adding, "I've always enjoyed figuring things out and finding a way to get a win, whether it be for my paper route customers [as a kid] or my country music fans, or the people I've been able to work with in design build and now facilities management. There's a win for everyone. And good business is making sure that your client is glad they spent their money with you. They do it again, and they'd tell their friends. That's it. That's what country music has in common with facilities management."
